Victory Capital Management Inc Spectrum Pharmaceuticals Inc Transaction History

Victory Capital Management Inc

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 27, 2023	SELL	$0.65 - $1.31 $302 - $610	-466 Reduced 2.27%	20,024 $19,000
Q1 2023 May 02, 2023	BUY	$0.38 - $1.07 $563 - $1,587	1,484 Added 7.81%	20,490 $15,000
Q4 2022 Feb 09, 2023	SELL	$0.32 - $0.52 $2 - $3	-7 Reduced 0.04%	19,006 $7,000
Q3 2022 Nov 02, 2022	SELL	$0.43 - $1.56 $962 - $3,491	-2,238 Reduced 10.53%	19,013 $8,000
Q2 2022 Aug 01, 2022	BUY	$0.7 - $1.4 $1,948 - $3,896	2,783 Added 15.07%	21,251 $17,000
Q1 2022 May 04, 2022	SELL	$0.63 - $1.59 $987 - $2,491	-1,567 Reduced 7.82%	18,468 $15,000
Q4 2021 Feb 07, 2022	SELL	$1.27 - $2.42 $810 - $1,543	-638 Reduced 3.09%	20,035 $25,000
Q3 2021 Nov 02, 2021	SELL	$2.15 - $3.82 $2,064 - $3,667	-960 Reduced 4.44%	20,673 $45,000
Q2 2021 Aug 03, 2021	BUY	$2.89 - $4.45 $5,652 - $8,704	1,956 Added 9.94%	21,633 $81,000
Q1 2021 May 04, 2021	SELL	$2.9 - $4.09 $2,485 - $3,505	-857 Reduced 4.17%	19,677 $64,000
Q4 2020 Feb 01, 2021	BUY	$3.38 - $5.14 $496 - $755	147 Added 0.72%	20,534 $70,000
Q3 2020 Nov 09, 2020	BUY	$2.99 - $4.9 $11,185 - $18,330	3,741 Added 22.47%	20,387 $83,000
Q2 2020 Aug 07, 2020	BUY	$2.11 - $3.38 $2,331 - $3,734	1,105 Added 7.11%	16,646 $56,000
Q1 2020 May 04, 2020	SELL	$1.83 - $3.45 $9,287 - $17,508	-5,075 Reduced 24.62%	15,541 $36,000
Q4 2019 Feb 06, 2020	BUY	$3.5 - $10.35 $19,610 - $57,991	5,603 Added 37.32%	20,616 $75,000
Q4 2019 Feb 04, 2020	SELL	$3.5 - $10.35 $1,081 - $3,198	-309 Reduced 2.02%	15,013 $38,000
Q3 2019 Nov 12, 2019	BUY	$7.03 - $9.7 $107,713 - $148,623	15,322 New	15,322 $127,000

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.